The MAPK (ERK) pathway: investigational combinations for the treatment of BRAF-mutated metastatic melanoma
J McCain - Pharmacy and Therapeutics, 2013 - pmc.ncbi.nlm.nih.gov
J McCain
Pharmacy and Therapeutics, 2013•pmc.ncbi.nlm.nih.govThe MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated
Metastatic Melanoma - PMC Skip to main content Here's how you know Official websites use
.gov A .gov website belongs to an official government organization in the United States. Secure
.gov websites use HTTPS A lock ( Locked padlock icon ) or https:// means you've safely
connected to the .gov website. Share sensitive information only on official, secure websites. PMC
home page Search Log in Dashboard Publications Account settings Log out Search… Search …
Metastatic Melanoma - PMC Skip to main content Here's how you know Official websites use
.gov A .gov website belongs to an official government organization in the United States. Secure
.gov websites use HTTPS A lock ( Locked padlock icon ) or https:// means you've safely
connected to the .gov website. Share sensitive information only on official, secure websites. PMC
home page Search Log in Dashboard Publications Account settings Log out Search… Search …
The arrival of ipilimumab and vemurafenib has provided oncologists with new choices in a field in which options were slim and the prognosis was grim. Combination therapy may lead to an improved survival benefit.
pmc.ncbi.nlm.nih.gov
